title: The economics of adalimumab for ulcerative colitis.
abstract: Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF-α blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. Future economic evaluations should choose appropriate comparators in the context of target-reimbursement decision making and focus on cost-effectiveness over a long time horizon.
authors.affiliation: Department of Clinical Epidemiology and Biostatistics, McMaster University Hamilton, Room H306 Martha Wing, St. Joseph's Healthcare Hamilton 50 Charlton Ave., E. Hamilton L8N 4A6, Canada.
authors.forename: Feng
authors.initials: F
authors.lastname: Xie
mesh_terms: D000068879:Adalimumab / Q000191:economics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D003362:Cost-Benefit Analysis; D003657:Decision Making; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000191:economics / Q000473:pathology; D012720:Severity of Illness Index
chemical_list: D000893:Anti-Inflammatory Agents; D000068879:Adalimumab
keywords: adalimumab; cost–effectiveness; economics; infliximab; ulcerative colitis